Literature DB >> 20677091

Design of virotherapy for effective tumor treatment.

Eva Garcia-Aragoncillo1, Ruben Hernandez-Alcoceba.   

Abstract

The use of viruses as therapeutic agents against cancer is an old concept that has had a significant revival in the past two decades, in parallel with advances in methods to modify viral genomes genetically. From the initial stage of proof of concept, the field of virotherapy quickly progressed to the clinical setting, where serious limitations, yet promising opportunities, were identified. After demonstrating good safety profiles in humans, the objective in virotherapy has become to improve the efficacy of oncolytic viruses. Virotherapy approaches include incorporating therapeutic genes, evaluating alternative viruses with stronger oncolytic potential, employing new methods to improve biodistribution, and establishing greater insight into the influence of the immune system on both the success and failure of therapies. This review summarizes the most significant advances in recent years in the design of virotherapy for effective tumor treatment.

Entities:  

Mesh:

Year:  2010        PMID: 20677091

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN: 1464-8431


  3 in total

1.  Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients.

Authors:  Robert A Adair; Victoria Roulstone; Karen J Scott; Ruth Morgan; Gerard J Nuovo; Martin Fuller; Deborah Beirne; Emma J West; Victoria A Jennings; Ailsa Rose; Joan Kyula; Sheila Fraser; Rajiv Dave; David A Anthoney; Alison Merrick; Robin Prestwich; Amer Aldouri; Oliver Donnelly; Hardev Pandha; Matt Coffey; Peter Selby; Richard Vile; Giles Toogood; Kevin Harrington; Alan A Melcher
Journal:  Sci Transl Med       Date:  2012-06-13       Impact factor: 17.956

Review 2.  Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs.

Authors:  Edward A Berger
Journal:  Curr Opin HIV AIDS       Date:  2011-01       Impact factor: 4.283

3.  Bacterial glucuronidase as general marker for oncolytic virotherapy or other biological therapies.

Authors:  Michael Hess; Jochen Stritzker; Barbara Härtl; Julia B Sturm; Ivaylo Gentschev; Aladar A Szalay
Journal:  J Transl Med       Date:  2011-10-11       Impact factor: 5.531

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.